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Platinum (Pt)-based chemotherapy is a broadly used therapeutic regimen against 
various cancers. However, the insufficient cellular uptake, deactivation by 
thiol-containing species and nonspecific distribution of cisplatin (CDDP) result in its 
low chemosensitivity as well as systemic side effects, which can largely constrain the 
employment of CDDP in clinical treatment. To circumvent these problems, in this 
study, polymeric nanoparticles were utilized to co-deliver a water-soluble CDDP 
derivative, poly (γ, L-glutamic acid)-CDDP conjugate, and a naturally occurring 
compound derived from broccoli, sulforaphane, which can achieve efficient 
glutathione (GSH) depletion, to improve the accumulation of CDDP in cancer cells. 
Results show that compared with combinational treatment of CDDP and SFN, the 
nanoparticles were more effectively internalized and could significantly reduce GSH 
content in breast cancer cells, leading to a notable increase in DNA-bound Pt and 
DNA damage-induced apoptosis. Moreover, in an orthotopic breast cancer model, the 
nanoparticles achieved a significantly higher tumor accumulation and exhibited a 
more powerful anti-tumor activity. Finally, this nano-enhanced chemotherapy was 
further confirmed in a liver cancer model with high-expression of GSH. Taken 
together, this sulforaphane-based nano-strategy holds great promise to enhance the 
sensitivity and therapeutic efficacy of Pt-based chemotherapy.
KEYWORDS: breast cancer, sulforaphane, cisplatin, nanoparticle, glutathione
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Breast cancer is one of the most common malignancies and the leading cause of 
cancer-related mortality in women.1 The platinum (Pt) anti-cancer agent cisplatin 
(cis-dichlorodiammineplatinum (II), CDDP) is broadly used alone or in combination 
with other therapeutics to combat breast cancer and other human cancers in clinic.2 
CDDP functions through forming both inter- and intra-strand crosslinks of nuclear 
DNA, which leads to DNA damage and cell apoptosis.3-5 Unfortunately, CDDP 
indiscriminately damages both tumor cells and normal cells following systemic 
administration,6 and exhibits dose-limiting side effects such as acute nephrotoxicity 
and hepatotoxicity,4,7 which largely restricts its clinical use.
Over the last two decades, nanoparticles (NPs)-enabled drug delivery systems have 
greatly advanced Pt-based chemotherapy.8,9 This delivery strategy is based on 
observations that NPs with a size between 20-200 nm can prolong the blood 
circulation of the loaded therapeutic agents and preferentially enhance tumor 
accumulation with reduced nonspecific distribution in healthy tissues owning to the 
enhanced permeability and retention (EPR) effect.10-12 NPs, such as long-circulating 
liposomes,13,14 water-soluble polymers,15,16 and polymeric micelles,17-19 have been 
widely utilized to facilitate CDDP delivery to the site of action. To date, poly 
(L-glutamic acid) is the most successful CDDP carrier.19 Particularly, the 
poly(ethylene glycol)-poly(L-glutamic acid) block copolymers, which can form 
polymeric micelles (NC-6004, developed by Nanocarriers®) after incorporating 
CDDP through the polymer-metal complex formation between carboxyl groups and 
CDDP, have entered phase III clinical trials in Japan and other Asian countries.19,20 
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Nevertheless, despite that NC-6004 and other nano-formulations have been 
demonstrated to markedly reduce the systemic toxicity of CDDP, the therapeutic 
efficacy has not significantly improved.7,21
One of the most important reasons for the unsatisfactory anti-tumor effect of 
Pt-based chemotherapy is the cytoplasmic detoxification of CDDP by elevated levels 
of thiol-containing species.22,23 Glutathione (GSH), the most abundant 
thiol-containing molecule in cells, can avidly bind with Pt to form Pt(GS)2 
conjugates,5 which are rapidly exported from tumor cells via ATP-dependent 
glutathione S-conjugate export pumps (GS-X pump).24 Numerous studies have proven 
that the chemosensitivity of cancer cells to CDDP can be largely restored by reducing 
the cellular concentration of GSH.4,19 For example, Chen and colleagues demonstrated 
that disulfiram, a prescription drug used to treat alcoholism, could decrease 
intracellular GSH and enhance CDDP efficacy.19 Sulforaphane (SFN), a naturally 
occurring isothiocyanate enriched in broccoli, is well-known for its cancer prevention 
effect, of which the mechanisms involve multiple targeted effects, including the 
induction of phase II antioxidant enzymes, cell cycle arrest and cellular apoptosis.25-29 
Moreover, SFN has been reported to deplete GSH by directly binding with GSH to 
form GSH-SFN complex, which can be further exported outside the cell.30,31 
Therefore, SFN has great translational potential for sensitizing Pt-based chemotherapy 
in a safe manner. Considering the aforementioned negative correlation between GSH 
content and tumor chemosensitivity, we propose that the therapeutic efficacy of 
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nano-formulated CDDP can be significantly improved by SFN-mediated GSH 
depletion, a hypothesis has not been explored so far. 
Here, a NPs-enabled co-delivery system consisting of a water-soluble poly(γ, 
L-glutamic acid)-CDDP (γ-PGA-CDDP) conjugate and SFN for breast cancer 
treatment is reported. NPs encapsulating two drugs (termed as SFN-CDDP-NPs) are 
prepared with amphiphilic copolymer methoxy poly(ethylene 
glycol)-poly(lactide-co-glycolide) (mPEG-PLGA), which can simultaneously deliver 
hydrophobic and hydrophilic drugs to the same cancer cell with a predetermined ratio 
after a single injection.32 Because of the better solubility and much higher 
encapsulation efficiency relative to CDDP,15,33 the γ-PGA-CDDP, formed by 
coordination interaction between carboxyl groups of γ-PGA and CDDP, is 
encapsulated into the hydrophilic core. Meanwhile, the hydrophobic SFN is loaded 
into the hydrophobic shell. The therapeutic efficacy of SFN-CDDP-NPs is 
systematically investigated and compared with free drugs and their combination both 
in vitro and in vivo. Moreover, mechanism studies, including quantification of cellular 
GSH contents and DNA-bound Pt, analysis of DNA damage and apoptosis related 
proteins are performed to better understand the role of SFN in sensitizing CDDP. 
RESULTS AND DISCUSSION
Synthesis and Characterization of SFN-CDDP-NPs. The water-soluble 
γ-PGA-CDDP conjugate was first prepared according to published methods,34 and 
successful synthesis was confirmed by Fourier transformed infrared (FT-IR) results 
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(Figure S1). SFN and γ-PGA-CDDP loaded mPEG-PLGA nanoparticles 
(SFN-CDDP-NPs) were fabricated using an adapted double emulsion method,32,34 
with hydrophilic γ-PGA-CDDP trapped in the hydrophilic core and hydrophobic SFN 
inserted in the hydrophobic layer (Scheme 1). The encapsulation efficiencies of SFN 
and CDDP in the optimized SFN-CDDP-NPs were 58.7 ± 4.5 % and 92.6 ± 3.6 %, 
respectively (Table S1), which gave an approximate molar ratio of 1:2 for SFN/CDDP. 
Transmission electron microscopy (TEM) images revealed a uniform spherical 
morphology of the NPs with the diameter of ~75.4 nm for blank mPEG-PLGA NPs 
and ~82.3 nm for CDDP-SFN-NPs (Figure S2a and 1a). The dynamic light scattering 
(DLS) results revealed that the hydrodynamic size of mPEG-PLGA NPs was ~93.4 
nm with ca. -14.4 mV of the zeta potential (Figure S2b,c). However, SFN-CDDP-NPs 
exhibited a slightly larger hydrodynamic diameter of ~98.2 nm with ca. -15.4 mV of 
the zeta potential (Figure 1b,c), which are supposed to assist in long blood circulation 
and passive tumor targeting.36,37 Furthermore, SFN-CDDP-NPs showed a good 
colloidal stability and maintained the structural integrity after incubation at 37 °C for 
3 days (Figure S3). Next, the drug release profile of SFN-CDDP-NPs was studied at 
pH 5.5 or 7.4 (Figure 1d). Both SFN and CDDP showed sustained release profiles 
within 48 h and exhibited higher release rates at pH 5.5 than 7.4. Notably, SFN was 
released from SFN-CDDP-NPs more rapidly than CDDP, which was favorable for 
decreasing intracellular GSH and preventing CDDP deactivation. 
Cellular Uptake and Intracellular Localization of NPs. In order to reveal the 
cellular uptake behavior of NPs, rhodamin B-labeled mPEG-PLGA NPs (RhoB-NPs) 
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with similar physicochemical properties to SFN-CDDP-NPs were prepared (Figure 
S4). Free RhoB and RhoB-NPs were incubated with MCF-7 cells and then observed 
using a confocal laser scanning microscope. As illustrated in Figure 2a, both free 
RhoB and RhoB-NPs showed time-dependent cellular uptake. At 1 h post-treatment, 
most of red fluorescence from RhoB-NPs was co-located with green fluorescence 
(LysoTraker Green stained lysosomes), indicating that RhoB-NPs were mainly 
internalized through endocytosis and entered into lysosomes. After a continuous 
internalization of RhoB-NPs for 6 h, abundant red fluorescence separated with the 
green fluorescence, suggesting their translocation from lysosomes to cytoplasm. By 
contrast, free RhoB was uniformly distributed in the cytoplasm all the time, indicating 
that small molecules were passively diffused into cells. In addition, the cells treated 
with RhoB-NPs showed a stronger RhoB signal in comparison with free RhoB group, 
most likely due to the more efficient endocytosis of NPs than passive diffusion of 
small molecules.38 The enhanced internalization of NPs was further confirmed by 
quantitative analysis using flow cytometry, where significantly higher RhoB signal 
was detected in RhoB-NPs treated cells compared to free RhoB treated cells (Figure 
2b,c). 
Enhanced Cytotoxicity in Vitro. The cytotoxicity of different formulations was 
studied using a cell counting kit-8 (CCK-8) assay. Consistent with the known 
biocompatibility of amphiphilic copolymer mPEG-PLGA,39 the mPEG-PLGA NPs 
exhibited no noticeable cytotoxicity in MCF-7 cells even at concentrations up to 800 
μg/mL (Figure S5), which was much higher than the dose used in the study. Although 
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CDDP exhibited dose-dependent toxicity towards MCF-7 cells (Figure 3a), the 
efficacy of CDDP was relative low with an IC50 of 72.59 μM (Table S2). SFN 
largely improved the chemosensitivity of CDDP with an IC50 of 48.97 μM for 
SFN+CDDP group. Encouragingly, SFN-CDDP-NPs achieved the most significant 
cytotoxicity with an IC50 as low as 11.59 μM, which is contributed to its enhanced 
cellular uptake compared with the free drug. Cell apoptosis is identified as the basic 
pharmacodynamic effect of CDDP.5 The apoptosis triggered by SFN-CDDP-NPs was 
determined quantitatively by flow cytometry analysis after Annexin V-FITC/PI 
co-staining (Figure 3b,c). The results showed that CDDP induced moderate apoptosis 
of MCF-7 cells with an apoptotic rate of 15.2%. By contrast, combination of SFN and 
CDDP raised the apoptotic rate to 39.5%. The most noteworthy result was 
SFN-CDDP-NPs, with a maximal apoptotic rate of 64.6%. 
Large amounts of studies have showed that CDDP-mediated DNA damage could 
activate p53 and further trigger p53-mediated apoptosis as well as PARP 
cleavage-mediated cellular decomposition.4,40 To confirm the mechanism of our 
nano-strategy, western blot analysis was conducted to analyze the levels of apoptosis 
related proteins. As shown in Figure 4a,b, the expression of γ-H2AX (marker of DNA 
damage), p53 and cleaved PARP were moderately up-regulated after CDDP treatment, 
suggesting a moderate increase of cell apoptosis. However, SFN+CDDP treatment led 
to a more significant increased expression of these apoptosis related proteins, 
demonstrating the supportive role of SFN to augment CDDP-mediated cell apoptosis. 
Unsurprisingly, the advantage of this combined formulation was further amplified by 
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NPs-enabled drug co-delivery, as SFN-CDDP-NPs treatment resulted in the most 
profound up-regulation of γ-H2AX, p53 and cleaved PARP. It is to be noted, 
anti-apoptotic protein Bcl-2 was slightly increased after CDDP treatment, which 
could be ascribed to the rescue response of cells and was correlated with CDDP 
tolerance.22 However, SFN treatment significantly inhibited CDDP-mediated Bcl-2 
up-regulation, which was in accordance with previous reports.41,42 Encouragingly, 
SFN-CDDP-NPs treatment led to the most notable reduction of Bcl-2 expression. 
These results strongly confirm the cell apoptosis mechanism of the significant 
cytotoxicity of SFN-CDDP-NPs. 
Increased Pt-DNA Complex by GSH depletion. GSH plays a vital role in CDDP 
detoxification, and depletion of GSH is suggested to increase the formation of 
Pt-DNA adducts and the chemosensitivity.4,19 To study the efficacy of SFN-mediated 
GSH depletion, the cellular GSH and DNA-bound Pt were measured after different 
treatments. The results showed that SFN effectively reduced GSH content in MCF-7 
cells (Figure 4c). Compared to free SFN and SFN+CDDP, SFN-CDDP-NPs achieved 
more profound depletion of GSH, presumably due to more efficient cellular uptake of 
NPs than free drug (Figure 2). The quantification of Pt content in the genomic DNA 
of MCF-7 cells revealed that, with the help of SFN-mediated GSH depletion, 
SFN+CDDP enabled more accumulation of DNA-bound Pt than CDDP (Figure 4d). 
Encouragingly, SFN-CDDP-NPs treatment resulted in the highest level of 
DNA-bound Pt, which led to the most significant cell cytotoxicity (Figure 4e). 
However, pretreatment with N-acetylcysteine (NAC, a precursor of GSH) largely 
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reduced the cytotoxicity of CDDP, SFN+CDDP and SFN-CDDP-NPs, which further 
emphasized the significance of GSH depletion to CDDP sensitization. Together, these 
results strongly suggest that robust depletion of GSH is indispensable for the 
increased formation of Pt-DNA adducts, which accounts for the superior therapeutic 
efficacy of SFN-CDDP-NPs in vitro.
Pharmacokinetics and Bio-Distribution in Vivo. The enhanced cytotoxicity in 
vitro prompted the evaluation of the therapeutic potential of SFN-CDDP-NPs in vivo. 
In order to reveal the pharmacokinetics and bio-distribution of NPs, indocyanine 
green-labeled mPEG-PLGA NPs (ICG-NPs) with similar physicochemical properties 
to SFN-CDDP-NPs were prepared (Figure S6). Free ICG and ICG-NPs were 
intravenously administrated into tumor-bearing mice and blood was withdrawn at 
predetermined time points. As shown in Figure S7, free ICG was rapidly eliminated 
from the blood. However, ICG-NPs were cleared much more slowly due to the 
prolonged blood circulation.34 In vivo whole-body imaging of tumor-bearing mice 
also confirmed the slower elimination and longer tumor retention of ICG-NPs than 
free ICG (Figure 5a). Ex vivo imaging results illustrated a much stronger fluorescent 
intensity of ICG-NPs in tumors compared to free ICG treatment (Figure 5b), which 
was benefited from the prolonged blood circulation and from the EPR effect-mediated 
tumor accumulation.11,43 The extended circulation time and greater tumor 
accumulation of SFN-CDDP-NPs compared to CDDP were further confirmed by 
quantification of Pt content in the blood, major organs and tumors using ICP-MS 
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(Figure S8). Taken together, SFN-CDDP-NPs can maintain higher effective drug 
concentrations and sustain a longer therapeutic period than free drugs. 
Anti-Tumor Therapy. The therapeutic effect of SFN-CDDP-NPs was investigated 
in an orthotopic breast tumor model. MCF-7 tumor-bearing mice were administrated 
with saline, SFN, CDDP, SFN+CDDP, SFN-CDDP-NPs, or SFN-CDDP-NPs/NAC. 
The tumor size increased rapidly in the saline group (Figure 5c), but CDDP treatment 
only moderately inhibited tumor progress with a tumor inhibition rate (TIR) of 39.1% 
(Figure 5d,e,f). Unlike the in vitro results, SFN barely enhanced the anti-tumor effect 
of CDDP (TIR = 47.2%) most likely due to the rapid elimination of small molecules 
(Figure S7). On the contrary, the tumor growth was more significantly inhibited in the 
SFN-CDDP-NPs group with a greater TIR of 74.1%. Additionally, pretreatment with 
NAC almost abolished the therapeutic benefit of SFN-CDDP-NPs, further 
emphasizing the key role of SFN for increased CDDP chemosensitivity. Moreover, 
the quantification of Pt content in tumors confirmed the highest CDDP accumulation 
in tumors of SFN-CDDP-NPs group (Figure S9a). Specifically, the quantification of 
Pt content in the genomic DNA of tumors revealed the greatest amount of 
DNA-bound Pt in SFN-CDDP-NPs group (Figure S9b). Therefore, the superior 
anti-tumor effect of SFN-CDDP-NPs is mainly ascribed to the significant increase of 
CDDP accumulation and DNA platination via NPs-mediated passive targeting and 
SFN-based GSH depletion. 
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To reveal the molecular mechanism of enhanced anti-tumor efficacy provided by 
SFN-CDDP-NPs, tumor sections were subjected to histopathological examination 
(Figure 6a,b). Hematoxylin and eosin (H&E) staining results showed that 
SFN-CDDP-NPs treatment caused the most cell death with a looser cell arrangement. 
The most significant increase in apoptosis related proteins γ-H2AX, p53 and cleaved 
PARP, as revealed by immunohistochemical (IHC) staining, was observed in tumor 
tissues after SFN-CDDP-NPs treatment. In addition, the up-regulation of 
anti-apoptotic protein Bcl-2 in response to CDDP treatment was significantly 
inhibited in the SFN-CDDP-NPs group. As a result, the most notable level of 
apoptosis was observed in the SFN-CDDP-NPs group with a highest percentage of 
TUNEL-positive cells (Figure 6c,d).
Afterwards, the safety profile of SFN-CDDP-NPs was evaluated. The mice treated 
with CDDP or SFN+CDDP exhibited a slight body weight loss after three intravenous 
injections (Figure S10), which is a commonly reported side effect of CDDP.4 
However, this was not observed in SFN-CDDP-NPs group. Even though H&E 
staining of major organs showed negligible changes in histomorphology in all groups 
(Figure S11), serum biochemistry and hematological blood cell tests demonstrated 
up-regulated AST and ALT and decreased platelets and white blood cells respectively 
in CDDP and SFN+CDDP treated mice (Figure S12 and S13), indicating the potential 
hepatotoxicity and myelosuppression of CDDP. In comparison, SFN-CDDP-NPs had 
negligible effect on all tested biomarkers, which demonstrated its safe profile with 
reduced systemic toxicity of CDDP.
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To explore the potential of this nano-strategy, the therapeutic effect of 
SFN-CDDP-NPs was further investigated in a HepG2 liver cancer model with 
high-expression of GSH (Figure S14).44 In this study, two control groups, 
CDDP-loaded NPs without SFN (CDDP-NPs) (Figure S15) and CDDP-loaded NPs 
with free SFN (CDDP-NPs+SFN), were used to validate the nano-enabled co-delivery. 
As shown in Figure S16, SFN-CDDP-NPs treatment resulted in the most significant 
tumor growth inhibition with a TIR of 62.2%, which was much higher than that of 
CDDP (TIR = 19.1%), SFN+CDDP (TIR = 24.8%), CDDP-NPs (TIR = 31.7%) or 
CDDP-NPs+SFN (TIR = 39.1%). Moreover, unlike CDDP or SFN+CDDP, 
SFN-CDDP-NPs treatment had no effect on mouse body weight (Figure S17). 
Mechanistic studies revealed that SFN-CDDP-NPs treatment led to the most 
significant cell apoptosis with the highest up-regulation of γ-H2AX, p53 and cleaved 
PARP and down-regulation of CDDP induced Bcl-2 expression (Figure S18). 
Collectively, these results strongly support that this nano-enable co-delivery strategy 
is applicable to treat tumor with high-expression of GSH.
CONCLUSION
In summary, SFN and CDDP co-loaded mPEG-PLGA NPs have been successfully 
prepared for enhanced breast cancer chemotherapy. After efficient internalization of 
SFN-CDDP-NPs by tumor cells, the more rapidly released SFN could notably 
decrease GSH content and thus significantly increase DNA-bound Pt, resulting in 
severe DNA damage and cellular apoptosis. Due to the improved chemosensitivity 
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and preferential tumor accumulation, SFN-CDDP-NPs greatly inhibited orthotopic 
breast cancer progression with reduced toxic side effects. Moreover, the enhanced 
anti-tumor efficacy of SFN-CDDP-NPs was successfully extrapolated to a liver 
cancer model with high-expression of GSH. Taken together, NPs-enabled co-delivery 
of SFN and CDDP provides a simple but robust strategy to improve the sensitivity 
and therapeutic efficacy of Pt-based chemotherapy.
EXPERIMENTAL SECTION
Materials. Methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) 
(mPEG-PLGA, molar ratio of D, L-lactic to glycolic acid, 75:25) was obtained from 
Jinan Daigang Biotechnology Co. Ltd (Jinan, China). Cisplatin (CDDP), was bought 
from Sigma-Aldrich. Sulforaphane (SFN) was obtained from Toronto Research 
Chemicals Inc. Poly (γ, L-glutamic acid) (γ-PGA, Mw 2000) was bought from 
Yuanye Bio-Technology Co., Ltd (Shanghai). LysoTracker Green DND 26 was 
obtained from Invitrogen. 35 mm confocal petri dishes (Cellvis, Mountain View, CA) 
were obtained from Hangzhou Xinyou Biotechnology Co., Ltd. (Hangzhou, China). 
RIPA lysis buffer (cat# R0010) and Hoechst 33342 (cat# C0030) were purchased 
from Solarbio Life Science (Beijing, China). Cell Counting Kit-8 (CCK-8) was 
bought from Dojindo Molecular Technologies (Tokyo, Japan).
Synthesis of γ-PGA-CDDP Conjugate. γ-PGA-CDDP conjugate was synthesized 
based on a reported method.33 Briefly, 20 mg CDDP and 35 mg γ-PGA were 
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dissolved in 5 ml deionized water. The mixture was stirred for 48 h at 37 °C, followed 
by excessive dialysis against deionized water to remove free CDDP.
Synthesis and Characterization of SFN-CDDP-NPs. SFN-CDDP-NPs was 
fabricated using amphiphilic copolymer mPEG-PLGA by an adapted double emulsion 
method as previously described.38 Briefly, 1 mL of dichloromethane containing 10 mg 
of mPEG-PLGA was mixed with 0.2 mL of γ-PGA-CDDP solution (0.5 mg CDDP) 
by sonication for 5 min. The solution and 250 µg SFN were added to 2 mL sodium 
cholate solution (5%, w/w) and further sonicated for 5 min. The resulting emulsion 
was then added to 10 mL of sodium cholate solution (1%, w/w) drop-by-drop and 
further stirred for 10 min. After removing dichloromethane through reduced vacuum 
evaporation, the resulting nanoparticles were obtained by centrifugation (13,000 rpm, 
10 min) and washed with deionized water twice. The encapsulation efficiencies of 
CDDP and SFN were determined by inductively coupled plasma mass spectrometry 
(ICP-MS) and high-performance liquid chromatography (HPLC), respectively. By 
replacing γ-PGA-CDDP with fluorescent dyes, the RhoB-NPs and ICG-NPs were 
prepared similarly. After stained with 1% uranyl acetate, the nanoparticles were 
characterized by transmission electron microscopy (HT7700, HITACHI, Japan). The 
diameter, polydispersity index (PDI) and zeta potential of the nanoparticles were 
measured by DLS (Malvern Instruments Ltd., UK).
Drug Release in Vitro. SFN-CDDP-NPs were transferred into a dialysis bag 
(MWCO 1000 Da, Spectrum). The drug release was performed at 37 °C in PBS 
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solution (pH 7.4 or pH 5.5). At the indicated time intervals, 0.2 mL of solution was 
acquired for SFN and CDDP quantification using HPLC and ICP-MS, respectively. 
0.2 mL of fresh PBS was replenished immediately.
Cell Culture and Animals. The human breast cancer cell line MCF-7 and human 
hepatocellular carcinoma cell line HepG2 were cultured in DMEM (WISENT, 
Canada) containing 10% FBS (Gibco BRL, NY, USA) at 37 °C in a humidified 
atmosphere containing 5% CO2. BALB/c nude mice (female, 6-8 weeks) were 
obtained from Vital River Laboratory Animal Technology Co. Ltd. The orthotropic 
breast tumor model was established by injecting 5×106 MCF-7 cells into the 
mammary fat pad of the mouse and the subcutaneous liver tumor model was 
generated by injecting 5×106 HepG2 cells into the right flank of the mouse. All 
animal experements were approved by the Institutional Animal Care and Use 
Committee of National Center for Nanoscience and Technology.
In Vitro Cytotoxicity Studies. MCF-7 cells were planted into 96-well plates (5,000 
cells/well). 12 h later, the cells were incubated with SFN, CDDP, SFN+CDDP, 
SFN-CDDP-NP at different concentrations for another 24 h. The cell viability was 
analyzed using a CCK-8 assay according to the manufacturer’s protocols. The 
cytotoxicity of different formulations (10 µM SFN, 20 µM CDDP) was also tested 
when cells were pre-treated with NAC (1 mM) for 1 h. 
Cellular Uptake and Intracellular Localization. MCF-7 cells were planted in 
confocal dishes (Nunc, USA). After overnight incubation, cells were treated with free 
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RhoB or RhoB-NPs for 1 or 6 h, then washed for 3 times using PBS before imaging 
using a laser confocal fluorescence microscopy (LSM710, Carl Zeiss, Germany). The 
nucleus and lysosome were stained using Hochest 3342 and LysoTracker Green DND 
26, respectively.
For quantitatively comparing cellular uptake between free RhoB and RhoB-NPs, 
MCF-7 cells were planted in 12-well plates. When reaching 70% confluent, cells were 
treated with free RhoB or RhoB-NPs for 6 h. After being harvested and washed for 3 
times using PBS, the cells were suspended in 0.2 ml PBS buffer and analyzed using a 
Accuri C6 flow cytometer (BD, USA).
Cell Apoptosis Study. MCF-7 cells were planted into 12-well plates (1×104 cells 
/well). After overnight incubation, cells were incubated with SFN, CDDP, 
SFN+CDDP and SFN-CDDP-NP for 24 h. Cells were then harvested and co-stained 
with PI and Annexin V using an Annexin V-FITC Apoptosis Detection Kit (BD, 
USA). Finally, the apoptosis of cells was tested using flow cytometric analysis.
Western Blot Assay. MCF-7 cells were collected after different treatments and 
total cellular protein was extracted. The concentration of protein was measured by a 
bicinchoninic acid protein assay kit (cat# 23225, Thermo). 50 μg proteins were used 
for SDS-PAGE electrophoresis and further transferred to 0.22 μm PVDF membranes. 
After incubated with p53 antibody (cat# 10442-1-AP, Proteintech), Bcl-2 antibody 
(cat# 12789-1-AP, Proteintech), PARP antibody (cat# 13371-1-AP, Proteintech) and 
γ-H2AX antibody (cat# 39117, Active Motif) at 4 °C overnight, these membranes 
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were washed for 3 times and incubated with secondary antibodies at RT for 1 h. After 
washed for 3 times, the immuno-reactivity was visualized after incubating with 
enhanced chemiluminescence (ECL) reagents. GAPDH was chosen as a loading 
control.
In Vitro GSH Test. MCF-7 cells were planted in 6 well plate (1×105 cells/well). 
After overnight incubation, cells were incubated with different formulations for 
another 6 h. Then, a same number of cells was collected from each group, and cellular 
GSH content was quantified using a Reduced GSH Detection Kit (Solarbio, Beijing). 
Quantification of DNA-bound Pt. The DNA platination was studied by 
quantification of DNA-bound Pt. Briefly, MCF-7 cells were planted into 6 well plate 
(1×105 cells/well) for 12 h. After treatment with different formulations for 6 h, cells 
were collected and total DNA was extracted using a Qiagen QIAamp DNA Blood 
Mini Kit (Qiagen, Hangzhou). The extracted DNA were digested by aqua regia at 
300°C, and the concentration of DNA-bound Pt was determined by ICP-MS. 
Pharmacokinetics and Bio-Distribution of NPs. Tumor-bearing mice were i.v. 
administrated with free ICG or ICG-NPs (ICG, 0.5 mg/kg). At predetermined time 
intervals, blood was acquired and analyzed using the IVIS in vivo imaging system 
(Lumina XR Series III, PerkinElmer). To study the bio-distribution of free ICG and 
ICG-NPs, the treated tumor-bearing mice were imaged using the IVIS in vivo imaging 
system at predetermined time points. After 24 or 48 h post-treatment, mice were 
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euthanized and major organs as well as tumor were acquired. The ex vivo fluorescent 
image was obtained using the IVIS in vivo imaging system.
Anti-Tumor Effects in Vivo. When tumor volume approached 150 mm3, mice 
were randomly divided to 6 groups (n = 5). Mice were i.v. administrated (3 times, 
every other day) with saline, SFN, CDDP, SFN+CDDP, SFN-CDDP-NPs or 
SFN-CDDP-NPs+NAC. The doses for SFN and CDDP were 0.59 mg/kg and 2 mg/kg, 
respectively. NAC (10 mg/kg) was intraperitoneally administrated 1 h before 
SFN-CDDP-NPs treatment. The tumor volume and body weight of each mouse were 
recorded every other day. Tumor volume was calculated using the formula V = 
0.5×L×W2, where L represents the length and W represents the width. In the end, 
mice were euthanized, and the tumors were acquired and weighed. 
To evaluate the anti-tumor activity in HepG2 tumor-bearing mice, mice were i.v. 
administrated (3 times, every other day) with saline, SFN, CDDP, SFN+CDDP, 
CDDP-NPs, CDDP-NPs+SFN, SFN-CDDP-NPs or SFN-CDDP-NPs+NAC.
Immunohistochemistry and TUNEL. The tumor was fixed with 4% 
paraformaldehyde and embedded in paraffin, which was further cut into 5 μm sections 
for immunohistochemical staining of p53, Bcl-2, γ-H2AX and cleaved PARP (cat# 
5625, Cell Signaling). To evaluate cellular apoptosis, the tumor section was stained 
using a terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate 
nick end labeling (TUNEL) assay kit (KeyGEN BioTECH, Nanjing) according to the 
manufacturer’s protocols.
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Hematology and Histopathology Examination. The murine blood was acquired 
from each group (n = 3) at the end of the experiment. After centrifugation at 4oC for 
20 min, the plasma was collected for blood biochemical analysis. The concentrations 
of aspartate aminotransferase (AST), alkaline phosphatase (ALP) and alanine amino 
transferase (ALT) were determined to evaluate liver function. The concentrations of 
blood urea nitrogen (BUN) and creatinine (CRE) levels were determined to evaluate 
renal function. The whole blood was also collected for white blood cells, red blood 
cells and platelets analysis.
Hearts, livers, spleens, lungs and kidneys of the treated mice were harvested, fixed 
with 4% paraformaldehyde and embedded in paraffin, which further stained with 
hematoxylin and eosin (H&E) before undergoing histopathological examination using 
an optical microscope (AMG EVOS xl core, Life Technologies, USA).
Statistics. All experiments were conducted in triplicate unless elsewhere indicated. 
The result was presented as mean ± standard deviation (S.D.). Student’s t test was 
used for statistical analysis. Difference between two groups was considered 
statistically significant when the two-sided p < 0.05.
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Scheme 1. Schematic diagram of the preparation of SFN-CDDP-NPs for 
improved anti-tumor therapy. (a) Schematic illustration of the synthesis of 
SFN-CDDP-NPs using a double emulsion method. (b) Proposed mechanism of 
SFN-CDDP-NPs for enhanced chemotherapy. The long circulating SFN-CDDP-NPs 
are accumulated in the orthotopic breast tumors via EPR effect. Endocytosis of 
SFN-CDDP-NPs allows the released SFN to deplete the abundant cellular GSH, 
which increases DNA platination-mediated cell apoptosis. 
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Figure 1. Characterization of SFN-CDDP-NPs. (a) TEM image of SFN-CDDP-NPs. 
Scale bar, 100 nm. (b) Size distribution of SFN-CDDP-NPs. (c) Zeta potential of 
SFN-CDDP-NPs. (d) Release profiles of SFN and CDDP at pH 5.5 or 7.4.
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Figure 2. Cellular uptake and subcellular distribution of RhoB-NPs. (a) Confocal 
laser scanning microscope images of MCF-7 cells treated with RhoB or RhoB-NPs 
for different time. The nuclei were labeled with Hoechst 33342 (blue) and lysosomes 
were labeled with LysoTracker (green). Scale bars, 50 μm. (b) Flow cytometric 
analysis of RhoB signal in MCF-7 cells after incubated with free RhoB and 
RhoB-NPs for 6 h. (c) Quantification of RhoB signal in MCF-7 cells. Data are 
presented as means ± SD (n = 3). ***P < 0.001.
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Figure 3. Evaluation of cytotoxicity. (a) Cytotoxicity of MCF-7 cells after different 
treatments for 24 h. (b) Apoptosis study of MCF-7 cells after different treatments for 
24 h. (c) Quantitative analysis of apoptotic cells. Data are presented as means ± SD (n 
= 3). *P < 0.05, **P < 0.01, ***P < 0.001. 
Page 31 of 35































































Figure 4. Mechanism analysis of SFN-CDDP-NPs induced cell apoptosis. (a) 
Western blot analysis after different treatments for 6 h. (b) Statistical analysis of the 
protein expression normalized to control. (c) Quantification of cellular GSH after 
different treatments for 6 h. (d) Pt content in the genomic DNA of MCF-7 cells after 
different treatments for 6 h. (e) Cell viability after different treatments for 24 h with or 
without NAC pretreatment. Data are presented as means ± SD (n = 3). *P < 0.05, **P 
< 0.01, ***P < 0.001.
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Figure 5. Bio-distribution and antitumor activity of SFN-CDDP-NPs in vivo. (a) 
In vivo fluorescence images of MCF-7 tumor-bearing mice at different time points. (b) 
Ex vivo fluorescence images of major organs as well as tumors, and their 
corresponding mean fluorescence intensity (MFI) analysis at 24 h and 48 h 
post-injection. (c) Tumor growth curves. (d) Photos of tumors from different groups. 
(e) Tumor weights at the end of experiment. (f) Tumor inhibition rates of different 
groups. Data are presented as means ± SD (n = 5). **P < 0.01, ***P < 0.001.
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Figure 6. Apoptotic analysis of MCF-7 tumors. (a) H&E and IHC images of tumor 
sections. Scale bars, 200 μm. (b) Statistical analysis of protein expression normalized 
to saline group. (c) TUNEL analysis of tumor section. Scale bars, 100 μm. (d) 
Quantification of TUNEL-positive cells. Data are presented as means ± SD (n=5). 
**P < 0.01, ***P < 0.001.
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Polymeric nanoparticles are utilized to co-deliver a water-soluble cisplatin (CDDP) 
derivative, poly (γ, L-glutamic acid)-CDDP conjugate, and sulforaphane, a naturally 
occurring compound derived from broccoli, that can achieve efficient glutathione 
(GSH) depletion, to increase the chemosensitivity of CDDP. Endocytosis of 
SFN-CDDP-NPs allows the released SFN to deplete the abundant cellular GSH, 
which increases DNA platination-mediated cell apoptosis.
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